To date, total serum IgE is approved as the biomarker for determining eligibility in severe asthma patients for omalizumab (a humanized recombinant monoclonal antibody with binding specificity at the FcεRI binding site of IgE) treatment [19]. The gene discussed is MS4A2; the disease is asthma.